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Introduction. Leptomeningeal carcinomatosis occurs in about 5% of cancer patients. Ocular involvement is a common clinical
manifestation and often the presenting clinical feature.Materials and Methods. We report the case of a 52-year old lady with optic
neuritis as isolated manifestation of neoplastic meningitis and a review of ocular involvement in neoplastic meningitis. Ocular
symptoms were the presenting clinical feature in 34 patients (83%) out of 41 included in our review, the unique manifestation of
meningeal carcinomatosis in 3 patients (7%). Visual loss was the presenting clinical manifestation in 17 patients (50%) and was
the most common ocular symptom (70%). Other ocular signs were diplopia, ptosis, papilledema, anisocoria, exophthalmos, orbital
pain, scotomas, hemianopsia, andnystagmus.Associated clinical symptomswere headache, altered consciousness,meningism, limb
weakness, ataxia, dizziness, seizures, and other cranial nerves involvement. All patients except five underwent CSF examination
which was normal in 1 patient, pleocytosis was found in 11 patients, increased protein levels were observed in 16 patients, and
decreased glucose levels were found in 8 patients. Cytology was positive in 29 patients (76%).Conclusion. Meningeal carcinomatosis
should be considered in patients with ocular symptoms even in the absence of other suggestive clinical symptoms.
1. Introduction
Leptomeningeal carcinomatosis results from dissemination
of malignant cells to leptomeninges and can be observed in
about 5% of patients with malignancies, but it is likely to
become more frequent with the increase of life expectancy
in cancer patients [1]. Neoplastic cells may spread to the
subarachnoid space through (1) arterial circulation or, less
frequently, through (2) retrograde flow in venous systems
or (3) as a direct consequence of preexisting brain metas-
tases or (4) through migration of neoplastic cells from
the original tumor along perineural or perivascular spaces
[2, 3]. Clinical manifestations can be highly variable and may
affect both central (CNS) and peripheral nervous system
(PNS). CNS involvement may lead to generalised symptoms
such as seizures, confusion, encephalopathy, or intracranial
hypertension as well as, less frequently, to focal neurological
symptoms, mainly consisting in hemiparesis or aphasia.
PNS involvement may present with lumbar and cervical
radiculopathies or cranial neuropathies [2]. Ocular symp-
toms even in the absence of other clinical symptoms may
represent the initialmanifestation ofmeningeal carcinomato-
sis. Thus, meningeal carcinomatosis should be considered in
the differential diagnosis in selected patients even if making
2 Neurology Research International
the diagnosis is often challenging. Diagnostic tools consist
mainly of contrast enhanced CT and MRI and lumbar punc-
ture. Treatment options such as radiation and intrathecal
chemotherapy are often palliative with an expected median
patient survival of 2 to 6 months [2].
2. Case Report
A 52-year old lady was referred to our hospital for acute
onset, ten days before hospitalization, of left orbital pain and
visual loss associated with mild frontal throbbing headache.
As symptoms progressed, she underwent ophthalmological
evaluation as outpatient six days after symptoms onset,
without evidence of significant visual loss and normal fundus
oculi examination. Ocular computed tomography performed
at that time was unremarkable. On subsequent ophthalmo-
logical evaluation five days later a significant visual loss in
the left eye was evident with substantially normal fundus
oculi examination. She underwent rightmastectomy andhor-
monal therapy (tamoxifen) for infiltrative breast carcinoma in
2007 followed by chemotherapy with AC (cyclophosphamide
and doxorubicin) for six months, followed by letrozole. She
was on regular followup.
On admission in August 2011 neurological examination
was normal except for mild anisocoria (left > right) with
detectable Markus Gunn sign, left eye visual loss, and global
reduction of deep tendon reflexes. She underwent contrast-
enhanced cerebral MRI showing nonspecific signal alteration
involving frontal subcortical and periventricularwhitematter
and focal contrast enhancement involving the left optic nerve
sheath (see Figure 1). VEP revealed destructured response,
reduced amplitude, and prolonged latency on the left (see
Figure 2). Lumbar puncture revealed increased cell count
(50 cells/mmc) with normal glucose and proteins. Oligo-
clonal bands were found on CSF but not in serum suggesting
intrathecal immune response. Cytology at that time was
negative for neoplastic cells and repeated ophthalmological
evaluations revealed further progression to complete visual
loss in the left eye. Serum antibodies (LAC, ACA, Anti-beta2-
glycoprotein ANA, anti-ds-DNA, ENA, c-ANCA, and p-
ANCA) were negative. A diagnosis of possible inflammatory
optic neuropathy was done. She was started on EV steroids
followed by oral tapering without improvement.
In about two months she started to complain of left hear-
ing loss. Brainstem auditory-evoked potentials were normal
on the left (see Figure 2) and audiological evaluation evi-
dencedmild neurosensorial failuremore evident on the right.
She underwent contrast-enhanced cerebral MRI in October
2011 showing increased enhancement of the left optic nerve
sheath. Repeated ophthalmological evaluation revealed bilat-
eral (left > right) papilledema and she was hospitalized. Neu-
rological examination on admission showed total blindness
in the left eye with absent pupillary response to direct light
stimulation. VEP revealed absent response on the left and
destructured response with normal amplitude and latency
on the right (see Figure 2). Cerebral and spine MRI were
unchanged except for nonspecific cerebellar enhancement.
She underwent repeated lumbar puncture showing further
increase of white cell count (105 cells/mmc) and reduced
glucose. Citology was positive for atypical epithelial cells (see
Figure 1). That was diagnostic for meningeal carcinomatosis.
She was referred to the Oncology Department for further
evaluation and treatment.
3. Search Strategies and Methods
References for this review were identified through a search of
PubMed from 1966 to March 8, 2012 with the terms “menin-
geal carcinomatosis,” “meningeal carcinomatosis and review,”
“meningeal carcinomatosis and optic neuritis,” “meningeal
carcinomatosis and ocular manifestations,” and “neoplastic
meningitis.” Reference lists of relevant articles were also
reviewed. Only articles with ocular manifestation as present-
ing or associated clinical features were included in our review.
4. Results
We found a total of 34 papers including 33 case reports
(34 patients) and 1 case series (7 patients). Information
about demographic details along with clinical, instrumental,
and radiological findings were recorded and summarized
in Table 1. In details we looked at latency between symp-
toms onset and diagnosis of meningeal carcinomatosis: the
mean time was 4 months, while the mean time between
primary tumor diagnosis and carcinomatosis diagnosis was
20 months. Six patients (14%) had a postmortem diagnosis.
Ocular symptoms were the presenting clinical feature in
34 out of 41 patients (83%) and were the only manifestation
of meningeal carcinomatosis in 3 patients (7%). Visual loss
was the presenting clinical manifestation in 17 patients
(50%) and was the most common ocular symptom (70%).
Visual loss was bilateral in 8 patients and unilateral in 2
patients. Sequential optic nerve involvement was observed
in 5 patients. Three patients had sudden onset of blindness.
Visual loss was progressive in other six patients.
Additional ocular manifestations were diplopia (18 pa-
tients, presenting manifestation in 16 patients), ptosis (8
patients), papilledema (4), anysocoria (3), exophthalmos (2),
orbital pain (2), scotomas (2), hemianopsia (1), and nystag-
mus (1).
Other common symptoms were headache (24 patients),
altered consciousness (10 patients), meningism (8 patients),
hemiparesis (7), ataxia (7), dizziness (6), and seizures (4). V
(4), VII (6), VIII (4), IX and X (2), and XII (1) cranial nerves
involvement has also been reported.
Twenty-three patients underwent enhanced MRI which
was diagnostic in 8 patients (35%). In 7 patients general-
ized meningeal enhancement was noted, and in 2 patients
meningeal enhancement was associated with optic nerves
enhancement, which was bilateral in 1 patient and unilateral
in the other one. Three patients had cranial nerves enhance-
ment, while isolated optic nerve enhancement was seen in
only 1 patient (unilateral on the first MRI and bilateral at the
second MRI). Other MRI findings included hydrocephalus
(1), infarction of basal nuclei (1), and cerebellar enhancement
(3).
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Figure 1: ((a)–(d)) Contrast-enhanced cerebralMRI showing diffuse enhancement of the left optic nerve at onset ((a), axial T1; (b), coronal T1)
and at 2 months followup ((c), axial T1 SE FSAT; (d) coronal T1 SE FSAT). ((e)-(f)) Cerebrospinal fluid cytology showing atypical epithelial
cells aggregates.
8 patients had normal MRI findings.
All patients except five underwent CSF examination
which was normal in 1 patient, and increased cells count was
found in 11 patients (range: 9–598/mm3), increased protein
levels were observed in 16 patients (range: 62–334mg/dL),
and decreased glucose levels were found in 8 patients (range:
5–43mg/dL). Citology was positive in 29 patients (76%).
The histology of the original tumor was highly variable
with solid tumors being more frequently associated with
meningeal carcinomatosis. The most common was gastric
cancer followed by lymphoma, breast, and lung cancer.
16 patients underwent chemotherapy (see Table 1), and
the mean life expectancy was 123 days (range 5–730 days).
Autopsy was obtained in 13 patients. See Table 1.
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(a) (b)
(c) (d)
Figure 2: Visual evoked potentials (VEPs) at onset ((a), (b)) and at two months follow-up ((c), (d)). (a)-(b): Response at 15 (a) and 30 (b) sec
showing destructured response, reduced amplitude and prolonged latency on the left and normal response on the right side. (c)-(d): Response
at 15 (c) and 30 (d) sec revealing absent response on the left and destructured response with normal amplitude and latency on the right side.
5. Discussion
Meninigeal carcinomatosis occurs in 1–5% of solid tumors
being adenocarcinoma the most common histology. The
highest leptomeningeal diffusion rate has been reported for
small cell lung cancer (11%) andmelanoma (20%).Meningeal
involvement occurs in about 5% of breast cancer patients
[1]. Neoplastic meningitis is more likely to occur in patients
with disseminated cancer, but in, respectively, 20% and 10%
of cases it may manifest after a disease-free period or as a
first manifestation of systemic tumors [2]. Current diagnostic
methods are limited and may fail to identify MC early
enough to prevent the escalation of neurological damage.
Thus meningeal carcinomatosis should be included in the
differential diagnosis in the presence of multifocal disease
but also considered in the evaluation of isolated syndromes
such as intracranial hypertension, cauda equine syndrome,
or cranial neuropathy. The most common manifestation of
cranial nerves involvement is diplopia due to VI cranial nerve
palsy, followed by III and IV involvement. V, VIII, and optic
nerve may also be affected [38].
Diagnostic workup includes CSF examination and neu-
roradiological studies. The presence of malignant cells
in the CSF is diagnostic, other supportive features are
increased opening pressure, pleocytosis, elevated proteins,
and decreased glucose levels. CSF cytology may be negative
in 65% of patients on initial examination, but only in 20% of
patients on second lumbar puncture [2]. CSF increased levels
of vascular endothelial growth factors have been proposed as
a promising biomarker with a reported sensitivity of 51–100%
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and a specificity of 73–100% for leptomeningeal metastases
[39].
Gadolinium-enhanced MRI is also useful for the diag-
nosis of meningeal carcinomatosis because enhancement on
MRI will reveal any irritation of leptomeninges resulting in
cranial nerves or intradural extramedullary enhancement on
spinal MRI.
Ocular involvement represents a frequent manifestation
of meningeal carcinomatosis. The reported frequency of
ocular signs may be as high as 90% [40].The present report is
an updated and systematic review of ocular manifestations of
neoplastic meningitis. Our data show that ocular symptoms
often represent the first clinical manifestation of meningeal
carcinomatosis (83%) and the only clinical manifestation
in a small proportion of subjects (7%). For this reason it
should be considered in the differential diagnosis even in the
absence of associated clinical symptoms more suggestive of
meningeal carcinomatosis such as headache (58%), altered
consciousness (24%), meningism (19%), focal signs (34%),
dizziness (15%), seizures (10%), and cranial nerves other
than ocular involvement (32%). The most common ocular
manifestation was visual loss (70%) followed by diplopia
(41%), ptosis (19%), papilledema (10%), anysocoria (7%),
exophthalmos (5%), orbital pain (5%), scotomas (5%), hemi-
anopsia (2%) and nystagmus (2%). Gadolinium-enhanced
MRI was diagnostic only in about one third of patients.
Meningeal enhancement was detected in about one third of
patients; in two of them (25%) it was associated with focal
optic nerve enhancement. In one patient (12%) contrast-
enhanced MRI revealed isolated optic nerve enhancement.
CSF examination was abnormal in all (36) but one patient.
The most common finding was increased proteins level
(44%), increased cells count (30%), and decreased glucose
(22%). Citology was positive in a high proportion of patients
(76%) with solid tumors being the more frequent. The first
CSF examination may be inconclusive, thus if clinical and
radiological suspicion persist and cell count is increased, a
repeated lumbar puncture is recommended.
6. Conclusion
Ocular involvement is a frequent and early clinical mani-
festation of meningeal carcinomatosis. Moreover clinicians
should be aware that ocular involvementmaymimic different
diseases as shown in our case report, where neoplastic optic
nerve involvement was indistinguishable from optic neuritis.
Thus meningeal carcinomatosis should be included in the
differential diagnosis of diplopia and visual loss in selected
patients because diagnosis is often challenging.
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